MCOP Therapy for Malignant Lymphoma

Abstract

Eighteen patients with malignant lymphoma were treated with a combination chemotherapy regimen consisting of mitoxantrone cyclophosphamide vincristine prednisolone (MCOP). Six patients achieved complete remission and eight partial remission. Good responses were obtained in all patients (four complete remission, two partial remission) who were treated by this regimen as a first chemotherapy. The side effects experienced by all patients on MCOP therapy were leukocytopenia and gastrointestinal toxicity. Cardiac toxicity was not encountered. The results suggest that MCOP therapy is an effective combination chemotherapy regimen for treatments of malignant lymphoma.